Effect of perioperative use of parecoxib on chronic post-surgical pain in elderly patients after hepatectomy: a prospective randomized controlled study

Table 2 Primary outcomes: incidence of CPSP at 3 months

Primary Outcomes	Parecoxib group	Placebo group	RR (95% CI)	P value
CPSP at 3 mo, N (%)	18 (35.3)	24 (44.4)	0.794 (0.493 ~ 1.279)	0.34
Worst-case scenario^a	23 (45.1)	24 (44.4)	1.015 (0.663 ~ 1.552)	0.95
Per-protocol analysis^b	18 (39.1)	24 (49.0)	0.799 (0.504 ~ 1.265)	0.33

CPSP chronic post-surgical pain; CI confidence interval; RR relative risk
^a All patients lost to follow-up in the parecoxib group developed CPSP, while all patients lost to follow-up in the placebo group did not develop the condition
^b Only patients who received allocated intervention and completed follow-up were included in his study

ISSN: 2050-6511